218 related articles for article (PubMed ID: 37175780)
21. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
22. Follicular cutaneous T-cell lymphoma: a clinicopathological study of nine cases.
Hodak E; Feinmesser M; Segal T; Yosipovitch G; Lapidoth M; Maron L; Bergman R; Sahar D; David M
Br J Dermatol; 1999 Aug; 141(2):315-22. PubMed ID: 10468808
[TBL] [Abstract][Full Text] [Related]
23. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
Willerslev-Olsen A; Litvinov IV; Fredholm SM; Petersen DL; Sibbesen NA; Gniadecki R; Zhang Q; Bonefeld CM; Wasik MA; Geisler C; Zhou Y; Woetmann A; Sasseville D; Krejsgaard T; Odum N
Cell Cycle; 2014; 13(8):1306-12. PubMed ID: 24621498
[TBL] [Abstract][Full Text] [Related]
24. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
25. Follicular mycosis fungoides.
Klemke CD; Dippel E; Assaf C; Hummel M; Stein H; Goerdt S; Orfanos CE
Br J Dermatol; 1999 Jul; 141(1):137-40. PubMed ID: 10417530
[TBL] [Abstract][Full Text] [Related]
26. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
27. T-cell receptor gene rearrangement in canine mycosis fungoides: further support for a canine model of cutaneous T-cell lymphoma.
Fivenson DP; Saed GM; Beck ER; Dunstan RW; Moore PF
J Invest Dermatol; 1994 Feb; 102(2):227-30. PubMed ID: 7906287
[TBL] [Abstract][Full Text] [Related]
28. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
29. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Chung CG; Poligone B
Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
[TBL] [Abstract][Full Text] [Related]
31. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
[TBL] [Abstract][Full Text] [Related]
32. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
33. Determination of T-cell clonality and expression profiles of Toll-like receptors signaling pathway genes and related miRNAs in patients with mycosis fungoides.
Seçme M; Dodurga Y; Demirkan NÇ; Kaçar N; Günel NS; Açıkbaş İ
Gene; 2024 Jan; 891():147825. PubMed ID: 37748629
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
35. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
36. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
Kopp KL; Kauczok CS; Lauenborg B; Krejsgaard T; Eriksen KW; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N; Woetmann A
Leukemia; 2010 Jun; 24(6):1179-85. PubMed ID: 20428208
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
40. Treatment of cutaneous T-cell lymphomas (CTCL) with extracorporeal photochemotherapy--preliminary report.
Nagatani T; Matsuzaki T; Kim S; Baba N; Osawa J; Sugiyama A; Komatsu H; Ichiyama S; Takahashi Y; Miyamoto H
J Dermatol; 1990 Dec; 17(12):737-45. PubMed ID: 2086618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
